12:23 PM EDT, 10/10/2024 (MT Newswires) -- ADMA Biologics ( ADMA ) shares were down more than 18% Thursday, a day after disclosing CohnReznick is no longer its independent registered public accounting firm as of the filing of Form 10-Q for the quarter ended Sept. 30.

The company has initiated the process of selecting a new accounting firm to audit its consolidated financial statements for the fiscal year ending Dec. 31, 2024, ADMA Biologics ( ADMA ) said Wednesday in a regulatory filing.

The company said in a separate filing Thursday that it does not expect any impact on the its previously issued financial guidance for 2024 and 2025.

Price: 16.57, Change: -3.76, Percent Change: -18.50